Colorectal Cancer

• Researchers at UCL and UCLH conducted a trial where patients with stage 2 or 3 colorectal cancer received just nine weeks of pembrolizumab immunotherapy before surgery, challenging the standard approach of surgery followed by months of chemotherapy. • Early results showed 59% of patients had no detectable cancer after completing immunotherapy and undergoing surgery, and after 33 months of follow-up, none of the patients have experienced a relapse. • This outcome represents a significant shift in colorectal cancer treatment protocols, suggesting that short bursts of targeted immunotherapy prior to surgery may deliver more durable results than conventional post-operative chemotherapy regimens.

• An NIH-funded mouse study shows chronic colitis induces long-lasting epigenetic changes in gut stem cells, boosting AP-1 transcription factor activity and tumor growth potential. • Researchers analyzed over 52,000 cells, finding damage memories persist more than 100 days after inflammation ends, heritable across new cells. • The findings from Broad Institute scientists explain how sustained inflammation elevates colorectal cancer risk through dynamic epigenome alterations.

March is Colorectal Cancer Awareness Month, with the CDC identifying colorectal cancer as the third most common cancer for both men and women in the United States. Cleveland Clinic registered dietitian Julia Zumpano emphasized that a healthy, diverse microbiome reduces inflammation, which is linked to increased colorectal cancer risk, and recommended dietary changes including high-fiber foods like whole grains, fruits, vegetables, and legumes alongside fermented and probiotic foods such as yogurt and kimchi. In addition to dietary modifications, regular physical activity has been shown to reduce colorectal cancer risk, though individuals experiencing persistent gastrointestinal symptoms should seek medical attention. The preventive approach focuses on gradual lifestyle transitions rather than overwhelming dietary overhauls.

Colorectal cancer has become the leading cause of cancer death for adults under 50 in the United States, yet a national survey by the Colorectal Cancer Alliance reveals only half of Americans know about convenient at-home screening options available to them. The survey found that nearly one-third of all Americans and almost half of adults under 45 reported doctors dismissing their stomach or bowel symptoms, indicating potential gaps in clinical recognition of warning signs in younger populations. More than one-quarter of adults don't follow through with recommended screening, with cost, fear, and lack of knowledge cited as primary barriers, though over 60 percent of respondents indicated they would pursue screening with better understanding of personal risk factors. March has been designated National Colorectal Cancer Awareness Month to address these critical knowledge gaps and encourage adoption of accessible screening methods.

A Colorectal Cancer Alliance survey finds only 50% of US adults know about at-home colorectal cancer screenings, contributing to it becoming the leading cancer killer for those under 50 with rising death rates. One-third of Americans, and nearly half under 45, report doctors dismissing stomach or bowel symptoms, while over 25% skip recommended screenings due to cost, fear, or lack of knowledge. More than 60% would screen if better informed of personal risk, prompting calls for awareness during National Colorectal Cancer Awareness Month. The nonprofit urges action to reverse trends where colorectal cancer deaths climb unlike most others.